Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Multimodality therapy for small-cell lung cancer]

A Yokoyama1

  • 1Dept. of Internal Medicine, Niigata Cancer Center Hospital.

Gan to Kagaku Ryoho. Cancer & Chemotherapy
|November 25, 1997
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Randomized phase II study of cisplatin, irinotecan and etoposide combinations administered weekly or every 4 weeks for extensive small-cell lung cancer (JCOG9902-DI).

Annals of oncology : official journal of the European Society for Medical Oncology·2003
Same author

T-helper 1 cells induce alveolitis but do not lead to pulmonary fibrosis in mice.

The European respiratory journal·2003
Same author

[Alcohol and oropharyngolaryngeal and digestive tract cancer].

Nihon Arukoru Yakubutsu Igakkai zasshi = Japanese journal of alcohol studies & drug dependence·2002
Same author

A study of the combination of gemcitabine hydrochloride (LY188011) and cisplatin in non-small-cell lung cancer: 3-week schedule.

International journal of clinical oncology·2002
Same author

A phase II study of paclitaxel plus cisplatin for advanced non-small-cell lung cancer in Japanese patients.

Cancer chemotherapy and pharmacology·2002
Same author

Three novel mutations of the RPGR gene exon ORF15 in three Japanese families with X-linked retinitis pigmentosa.

American journal of medical genetics·2001

Combined chemoradiotherapy, including early thoracic radiotherapy (TRT), significantly improves survival for limited small-cell lung cancer (LS-SCLC). Concurrent TRT with cisplatin and etoposide is considered optimal for this disease.

Area of Science:

  • Oncology
  • Thoracic Medicine
  • Radiation Oncology

Context:

  • Limited small-cell lung cancer (LS-SCLC) presents unique treatment challenges.
  • Chemotherapy alone has shown limitations in achieving long-term survival for LS-SCLC.
  • Optimal timing and combination of therapies are crucial for improving patient outcomes.

Purpose:

  • To evaluate the efficacy of combined chemoradiotherapy versus chemotherapy alone in limited small-cell lung cancer.
  • To determine the impact of early versus delayed thoracic radiotherapy (TRT) on survival rates.
  • To establish the optimal multimodal treatment strategy for LS-SCLC.

Summary:

  • Combined chemoradiotherapy is superior to chemotherapy alone for limited small-cell lung cancer.
  • Early thoracic radiotherapy (TRT) demonstrates superior long-term survival rates compared to delayed TRT.

Related Experiment Videos

  • Concurrent TRT with cisplatin and etoposide is considered the optimal standard treatment in North America and Japan, significantly improving median and 3-year survival rates.

    • Impact:

    • Multimodality therapy, particularly concurrent chemoradiotherapy, has substantially improved survival metrics in LS-SCLC.
    • Current treatment strategies have led to median survival exceeding 20 months and 3-year survival rates over 40%.
    • Further advancements in local and systemic therapies are essential for achieving curative-intent treatment in LS-SCLC.